Telix Pharmaceuticals (Telix Pharmaceuticals) Total Liabilities : $166.9 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Total Liabilities?

Telix Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $166.9 Mil.

Telix Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2022 ($118.32 Mil) to Jun. 2023 ($157.23 Mil) and increased from Jun. 2023 ($157.23 Mil) to Dec. 2023 ($166.93 Mil).

Telix Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($77.01 Mil) to Dec. 2022 ($118.32 Mil) and increased from Dec. 2022 ($118.32 Mil) to Dec. 2023 ($166.93 Mil).

Telix Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Telix Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Total Liabilities Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

22.40

59.34

77.01

118.32

166.93

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial								77.01	77.68	118.32	157.23	166.93

Telix Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Telix Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	105.36	+	(10.633	+	50.714
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.221)
	=	166.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	266.601	-	99.673
	=	166.9

Telix Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	105.36	+	(10.633	+	50.714
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.221)
	=	166.9

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	266.601	-	99.673
	=	166.9

Telix Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.